Inebilizumab

Inebilizumab is a monoclonal antibody designed for the treatment of neuromyelitis optica, a rare neurological condition. It is marketed under the brand name Uplizna.

Mechanism of Action

Inebilizumab works by binding to a specific protein, CD19, found on the surface of B cells. By doing this, it helps to reduce the number of B cells in the body, which are believed to play a key role in the development of neuromyelitis optica.

Uses

Inebilizumab is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Side Effects

Common side effects of Inebilizumab include urinary tract infection, back pain, joint pain, headache, and high blood pressure. Serious side effects can include infection, liver problems, and depression.

History

Inebilizumab was approved by the Food and Drug Administration (FDA) in June 2020, making it the second drug approved for the treatment of NMOSD.

References

<references />

See Also

• Monoclonal antibodies
• Neuromyelitis optica
• CD19
• B cells
• Food and Drug Administration

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!